Lixte Biotechnology Holdings Stock Today
| LIXTW Stock | USD 0.07 0.01 10.71% |
Performance6 of 100
| Odds Of DistressOver 78
|
Lixte Biotechnology is selling for under 0.075 as of the 5th of June 2024; that is -10.71 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0715. Lixte Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Lixte Biotechnology Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of May 2024 and ending today, the 5th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of November 2020 | Category Healthcare | Classification Health Care |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in East Setauket, New York. More on Lixte Biotechnology Holdings
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lixte Stock Highlights
| CEO President | Bastiaan MSc | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Lixte Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lixte Biotechnology's financial leverage. It provides some insight into what part of Lixte Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Lixte Biotechnology Holdings (LIXTW) is traded on NASDAQ Exchange in USA. It is located in 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 and employs 3 people. Lixte Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.49 M. Lixte Biotechnology classifies itself under Biotechnology sector and is part of Health Care industry.
Lixte Biotechnology Holdings has accumulated about 1.08 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lixte Biotechnology Probability Of Bankruptcy
Lixte Biotechnology Historical Income Statement
Lixte Stock Against Markets
Lixte Biotechnology Corporate Management
| John Kovach | Chairman, Founder | Profile | |
| Esq JD | Consultant | Profile | |
| James MD | Chief Officer | Profile | |
| Robert Weingarten | VP CFO | Profile | |
| Eric JD | Chief Officer | Profile | |
| Francis Johnson | Consultant | Profile |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.